Press release archive 2007

Friday, 14 December 2007
ARIMIDEX Significantly Superior to Tamoxifen in Reducing Risk Of Breast Cancer Returning and Increasing Disease-Free Survival Landmark results from one of the world’s largest breast cancer trials, presented today at the San Antonio Breast Cancer Symposium (SABCS) USA, and published online in The Lancet Oncology, reinforce that ARIMIDEX (anastrozole) is significantly superior to tamoxifen in reducing the risk of breast cancer returning and in increasing disease-free survival (DFS) in postmenopausal women with hormone receptor positive (HR+) early disease.
Wednesday, 12 December 2007
AstraZeneca Files Patent Infringement Actions in Response to Crestor™ ANDAs AstraZeneca today announced that it has filed patent infringement actions in United States District Court, District of Delaware, against seven generic drug manufacturers, which have submitted Abbreviated New Drug Applications (ANDAs) for Crestor™
Monday, 10 December 2007
FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM® (Esomeprazole Magnesium) The US Food and Drug Administration (FDA) today issued its final assessment of two small, open, long-term, clinical studies in patients with gastro-esophageal reflux disease (GERD), comparing anti-reflux surgery with either omeprazole (SOPRAN study) or NEXIUM ® (LOTUS study) treatment.
Friday, 7 December 2007
AstraZeneca Presents its Global Biologics Organisation, MedImmune, at 2007 Analyst and Investor R&D Day AstraZeneca (AZN) today holds an R&D day for analysts and investors at the headquarters of its global biologics organisation, MedImmune, in Gaithersburg, Maryland, USA, to present its recently expanded world-class biologics expertise. At the meeting, which will run from 9:00 AM to 3:00 PM EST, senior leaders from MedImmune will present the Company’s highly developed capabilities in antibody and vaccine discovery, development, production and commercialisation within the broader context of AstraZeneca’s R&D
Wednesday, 5 December 2007
AstraZeneca Presents New Depression and Anxiety Results for SEROQUEL XR™ The first data from the SEROQUEL XR™ (quetiapine fumarate) Extended Release clinical development programme in major depressive disorder (MDD) and generalised anxiety disorder (GAD) were presented at the 7th International Forum on Mood and Anxiety Disorders (IFMAD) in Budapest, AstraZeneca announced today
Thursday, 29 November 2007
AstraZeneca Receives Six Months Paediatric Exclusivity Patent Extension For ARIMIDEX® From The FDA AstraZeneca today announced that the United States (US) Food and Drug Administration (FDA) has granted an additional six month period of exclusivity to market ARIMIDEX® (anastrozole) for its licensed breast cancer indications until June 2010. Prior to paediatric exclusivity being granted by the FDA, the patent was due to expire in December 2009.
Monday, 19 November 2007
EPO Rules AstraZeneca MUPS® Patent Valid The European Patent Office (EPO) Opposition Division today ruled that the European patent for a MUPS ® formulation (EP 723 437) is still valid in amended form, despite four oppositions from generic drug manufacturers.
Friday, 16 November 2007
Seroquel XR™ Receives Approval from FDA for Maintenance Treatment of Schizophrenia AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR™ (quetiapine fumarate) Extended-Release Tablets for maintenance treatment of schizophrenia in adult patients. On May 17, 2007, the FDA approved SEROQUEL XR for the acute treatment of schizophrenia in adult patients.
Friday, 9 November 2007
CRESTOR® Now Indicated To Slow The Progression Of Atherosclerosis In Patients With Elevated Cholesterol AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) has approved CRESTOR® (rosuvastatin calcium) as an adjunct to diet to slow the progression of atherosclerosis in patients with elevated cholesterol. This new indication gives CRESTOR an important differentiator from competitors in the cholesterol-lowering marketplace.
Wednesday, 7 November 2007
AstraZeneca launches and prices a debut GBP 350 million sterling bond and a EUR 750 million eurobond AstraZeneca PLC, rated A1 (stable) by Moody's and AA- (stable) by Standard & Poor's, announces the successful pricing of a debut sterling bond for GBP 350 million and a Euro 750 million eurobond transaction (the “Bonds”). The proceeds of the issue will be used for general corporate purposes and to repay a portion of the outstanding US commercial paper taken on in connection with the acquisition of MedImmune.